PHARMACEUTICAL 2026

Zoetis Inc
Rank 103 of 178



PHARMACEUTICAL 2026

Zoetis Inc
Rank 103 of 178

The relative strengths and weaknesses of Zoetis Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Zoetis Inc compared to the market average is the variable Comprehensive Net Income, increasing the Economic Capital Ratio by 67% points.The greatest weakness of Zoetis Inc is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 139% points.

The company's Economic Capital Ratio, given in the ranking table, is 208%, being 22% points below the market average of 229%.

Input Variable	Value in 1000 USD
Assets, Current	6,768,000
Cost of Goods Sold	2,666,000
Intangible Assets	3,765,000
Liabilities, Current	2,235,000
Liabilities, Non-Current	9,486,000
Other Assets	1,253,000
Other Compr. Net Income	106,000
Other Expenses	1,088,000
Other Liabilities	415,000
Other Net Income	36,000
Other Revenues	9,467,000
Property and Equipment	3,681,000
Research and Development	698,000
Selling, General and Administrative Expense	2,378,000

Output Variable	Value in 1000 USD
Assets	15,467,000
Liabilities	12,136,000
Expenses	6,830,000
Revenues	9,467,000
Stockholders Equity	3,331,000
Net Income	2,673,000
Comprehensive Net Income	2,726,000
BaseVar	22,021,000
ECR before LimitedLiability	72%
Economic Capital Ratio	208%